How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,518 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Diarrhoea in Adult Cancer Patients: ESMO Clinical Practice Guidelines

(PPIs), contact with possibly infected persons, use of laxatives and other over-the-counter medications] and previous admission for diarrhoea. Earlier history of gastrointestinal diseases [e.g. in?am- matory bowel disease (IBD)] should also be assessed before the ini- tiation of antineoplastic therapy. Patients should be asked about incontinence as a factor included in the grading, as they may be reluctant to volunteer the information. Fever should be assessed, and temperature meas- ured. Other (...) therapies Classofdrug Drug Incidenceof diarrhoea(%) Incidenceof grade3and 4diarrhoea(%) Anti-EGFR Ge?nitib 26–52 1–5 Erlotinib 18–57 3–6 Afatinib 87–95 14–22 Cetuximab 13–28 4–28 Panitumumab 21 8–20 Anti-HER2 Lapatinib 47–75 3–14 Trastuzumab 2–63 2–6 Pertuzumab 67 5–8 Anti-BRAF Vemurafenib 5–6 0 Dabrafenib 1 0 Anti-MEK Cobimetinib 45–50 4 Trametinib 45–50 4 Anti-EML4/ALK Crizotinib 50–60 0 Anti-VEGF Bevacizumab 20 2–7 A?ibercept 58–69 13–19 Multi-targeted TKI Imatinib 20–26 1 Pazopanib 52 4 Sunitinib 44

2018 European Society for Medical Oncology

62. Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea Full Text available with Trip Pro

at Home and to Animals in Public Settings: Risks to Children Pickering et al [51] Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative Rubin et al [208] Mode Title URL Author/Issuing Agency International travel Expert Review of the Evidence Base for Prevention of Travelers’ Diarrhea DuPont et al [113] Medical Considerations Before International Travel Freedman et al [207] The Yellow Book CDC Travelers Health CDC Immunocompromised hosts Guidelines (...) etiology. b. Ill immunocompetent people with fever documented in a medical setting, abdominal pain, bloody diarrhea, and bacillary dysentery (frequent scant bloody stools, fever, abdominal cramps, tenesmus) presumptively due to Shigella . c. People who have recently travelled internationally with body temperatures ≥38.5°C and/or signs of sepsis (weak, low). See . 31. The empiric antimicrobial therapy in adults should be either a fluoroquinolone such as ciprofloxacin, or azithromycin, depending

2017 Infectious Diseases Society of America

63. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

not so identified.xiii Definition of key terms Serodiscordant couples are couples in which one partner is living with HIV and the other is HIV-negative. A couple refers to two people in an ongoing sexual relationship; each of these people is referred to as a partner in the relationship. How individuals define their relationships will vary according to their cultural and social context. Antiretroviral therapy ARV (antiretroviral) drugs refer to the medicines used to treat HIV. ART (antiretroviral (...) ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTIONCONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION 2016 RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH SECOND EDITIONWHO Library Cataloguing-in-Publication Data Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – 2nd ed. 1.HIV Infections – drug therapy. 2.HIV Infections – prevention

2016 World Health Organisation HIV Guidelines

64. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. From 1 Professor and Chair, Department of Nutrition Sciences, University of Alabama at Birmingham, Director, UAB Diabetes Research Center, GRECC Investigator & Staff Physician, Birmingham VA Medical Center, Birmingham, Alabama; 2 Director, Metabolic Support, Clinical Professor of Medicine, Division (...) School of Medicine, Internal Medicine, Endocrinology, Pediatrics, Pediatric Endocrinology, New Haven, Connecticut; 7 Walter Reed National Military Medical Center, Diabetes Obesity & Metabolic Institute, Bethesda, Maryland; 8 Assistant Clinical Professor, Mount Sinai School of Medicine, NY, ProHealth Care Associates, Division of Endocrinology, Lake Success, New York; 9 Center for Weight Management, Division of Endocrinology, Diabetes and Metabolism, Scripps Clinic, San Diego, California. Address

2016 American Association of Clinical Endocrinologists

65. Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.

in the prevention of antibiotic induced diarrhea and Clostridium difficile diarrhea. The chosen population consists of 190 hospitalized patients taking antibiotics. Preselected and randomized patients will take probiotics once daily until 1 week after the course of antibiotic is over or a placebo with 0 CFU. The primary outcome is to detect the occurrence of an antibiotic-associated diarrhea. The secondary outcome is to assess the presence of Clostridium difficile toxins in stool culture. Condition or disease (...) a placebo regimen. Primary Purpose: Prevention Official Title: Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea; A Randomized Double Blind Placebo Controlled Trial. Estimated Study Start Date : September 1, 2018 Estimated Primary Completion Date : December 31, 2018 Estimated Study Completion Date : March 31, 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment

2018 Clinical Trials

66. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (Abstract)

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety (...) and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC.This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end

2020 EvidenceUpdates

67. Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial

on admission and during follow up measured by patient interview Combined safety endpoints in regard to side effects from nutritional therapy [ Time Frame: measured at day 30 ] Number of participants with side effects from nutritional therapy including (a) adverse gastrointestinal effects (diarrhea, nausea, vomiting, abdominal pain) assessed by patient interview (yes/no) b) Complications due to tube feeding or center catheter for parenteral nutrition assessed by medical chart review (c) Refeeding syndrome (...) Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2015 Clinical Trials

68. Massage therapy for the treatment of children's diarrhea: a systematic review and meta-analysis

Massage therapy for the treatment of children's diarrhea: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used

2017 PROSPERO

69. Systematic review of the effectiveness of zinc as an adjunct therapy in diarrhoea treatment in children 0-5 years

Systematic review of the effectiveness of zinc as an adjunct therapy in diarrhoea treatment in children 0-5 years Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence (...) by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about

2017 PROSPERO

70. Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25

Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25 1 Translation of addendum A17-53 Etelcalcetid (sekundärer Hyperparathyreoidismus) – Addendum zum Auftrag A17-25 (Version 1.0; Status: 27 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 27 October 2017 1.0 Commission: A17-53 Version: Status: IQWiG Reports (...) – Commission No. A17-53 Etelcalcetide (secondary hyperparathyroidism – Addendum to Commission A17-25 1 Addendum A17-53 Version 1.0 Etelcalcetide – Addendum to Commission A17-25 27 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Etelcalcetide (secondary hyperparathyroidism – Addendum to Commission A17-25 Commissioning agency: Federal Joint Committee Commission awarded on: 9 October 2017

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

71. Systemic therapy for recurrent epithelial ovarian cancer.

information on the potential harms of systemic therapy. Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinician. Cancer Care Ontario (CCO) makes no representations or guarantees of any kind whatsoever regarding the report content or its use (...) Systemic therapy for recurrent epithelial ovarian cancer. Systemic therapy for recurrent epithelial ovarian cancer. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed

2017 National Guideline Clearinghouse (partial archive)

72. Systemic Therapy for Stage IV Non?Small-Cell Lung Cancer Update

factor receptor ( EGFR ), anaplastic lymphoma kinase ( ALK ), or proto-oncogene receptor tyrosine kinase ( ROS1 ) targets; and other drug classes and treatment settings that were covered in the 2015 update. Since the 2015 update, there have been many advances in the management of these patients, specifically with immune therapy with checkpoint inhibitors. Cancer immunotherapy allows some patients to live longer with a better quality of life than chemotherapy; however, not all patients respond (...) or III RCTs or meeting abstracts with fully available presentations Minimal sample size of 20 patients for immune checkpoint therapy or targeted therapy studies (50 patients for chemotherapy) Studies must have met enrollment targets Used intent-to-treat analysis for primary and secondary outcomes Independent determination of response For non-RCTs used to support recommendations, results must have been consistent Articles were excluded from the systematic review if they were meeting abstracts

2017 American Society of Clinical Oncology Guidelines

73. Chronicles of a Second Year Medical Student

Chronicles of a Second Year Medical Student Chronicles of a Second Year Medical Student – Clinical Correlations Search Chronicles of a Second Year Medical Student August 6, 2015 5 min read By Matthew Siow Peer Reviewed Day 1 of the medicine rotation: complete. I was on long call today, which meant three things. One, the hours during which I had to pretend I knew something were longer. Two, I saw a lot of things I had never seen before, from more common things like COPD exacerbations and acute (...) stem. Second, what on earth did I just read? Third, ELEVEN answer choices? Is that even legal? Seriously, who comes up with this stuff? Okay, focus. Like the awesome medical student I am, I remember reading in Harrison’s Principles of Internal Medicine about the classic triad of renal cell carcinoma: hematuria, flank pain, and a palpable mass in the flank or abdomen [1]. It has to be B. Your answer: B. Hematuria, flank pain, palpable mass Correct answer: K. There is really no classic triad

2015 Clinical Correlations

74. A Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

, is a congenital anomaly/birth defect or is medically significant. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug. Number of Participants with Any Markedly Abnormal Standard Safety Laboratory Values [ Time Frame: From First dose date of study drug through 30 days after the last dose of study drug (Up to 25 months) ] Clinical (...) , their analogues, or excipients in the various formulations of any agent. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or GI procedure that could interfere with the oral absorption or tolerance of treatment. Treatment with any investigational products within 30 days before randomization. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study

2018 Clinical Trials

75. Comparison of Therapy in Treatment of Patients With Helicobacter Pylori Infection: Concomitant Versus Hybrid Therapy.

Mestrovic, Sponsor-Investigator, University of Split, School of Medicine ClinicalTrials.gov Identifier: Other Study ID Numbers: 003-08/18-03/0001 First Posted: June 28, 2018 Last Update Posted: June 28, 2018 Last Verified: June 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Antonio Mestrovic, University of Split, School of Medicine: Helicobacter pylori, eradication, hybrid therapy (...) a total of 174 patients (87 patients in each therapy group), and the planned duration is 6 months. Condition or disease Intervention/treatment Phase Helicobacter Pylori Infection Drug: Concomitant therapy Drug: Hybrid therapy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 174 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official

2018 Clinical Trials

76. A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer Actual Study Start Date : October 24, 2018 Estimated Primary Completion Date : November 30, 2021 Estimated Study Completion Date : July 31, 2023 Resource links provided by the National Library of Medicine related (...) hepatitis B (eg, hepatitis B surface antigen reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [qualitative] is detected). Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection. Patient has had investigational therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day

2018 Clinical Trials

77. Diarrhea Secondary to Medications

to Medications Diarrhea Secondary to Medications Aka: Diarrhea Secondary to Medications , Drug-Induced Diarrhea , Medication-Induced Diarrhea From Related Chapters II. Causes: Medication Class See s (e.g. ) s Amoxicillan-Clavulanate ( ) Chemotherapeutic agents Antiinflammatory medications S s ( ) Antihypertensives s s ( ) May cause a sprue-like not seen with other s Endocrine agents ( ) ( ) ( ) Gastrointestinal Agents or calcium containing s s (e.g. , senna) s (e.g. ) s (e.g. ) Metoclopramide (Reglan (...) Diarrhea Secondary to Medications Diarrhea Secondary to Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea Secondary

2015 FP Notebook

78. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

the intention-to-treat population, which included all patients in cohort 1 who were randomised and received at least 1 dose of blinded study drug (n=148 in the placebo arm and n=220 in the vedolizumab arm). The maintenance study Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 62analyses also used the intention-to-treat (...) or became intolerant to a TNF-alpha inhibitor whereas the comparator study included only those whose disease lost response or became intolerant to TNF-alpha inhibitor therapy. Results for the 'mixed' population (that is, all patients regardless of TNF-alpha inhibitor status) were provided as a secondary analysis. The company noted that the placebo response rates in GEMINI II were inexplicably higher than in the other studies and considered that this could bias the results against vedolizumab

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

79. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

cannot tolerate, or have medical contraindications for, such therapies. Golimumab is recommended only if the company provides the 100 mg dose of golimumab at the same cost as the 50 mg dose, as agreed in the patient access scheme. 1.2 The choice of treatment between infliximab, adalimumab or golimumab should be made on an individual basis after discussion between the responsible clinician and the patient about the advantages and disadvantages of the treatments available. This should take (...) and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. 1.4 Infliximab, adalimumab or golimumab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Specialists should then discuss the risks and benefits of continued treatment with the patient, and their parent or carer if appropriate: Infliximab, adalimumab and golimumab for treating

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

80. Cardiovascular Disease: Secondary Prevention

Organization diagnostic criteria—who have failed to achieve an LDL 400 mg/dL. Bile acid sequestrants should be avoided for patients with TG = 300 mg/dL. • Cholestyramine has many drug interactions due to its ability to reduce absorption of other medications. Other drugs should be administered at least 1 hour before or 4–6 hours after cholestyramine. 9 ACE Inhibitor or ARB Therapy Table 3. ACE inhibitor or ARB therapy for secondary prevention of ASCVD Line Medication Initial dose Maximum dose 1 st ACE (...) ) or PCI with stent. Table 4. Antiplatelet therapy for secondary prevention of ASCVD Line Medication Initial dose Maximum dose 1 st Aspirin 81 mg daily 81 mg daily 2 nd Clopidogrel 1 75 mg daily 75 mg daily 1 Clopidogrel is equally effective in patients with ASCVD who have a contraindication or intolerance to aspirin. 10 Lowering Triglycerides to Prevent Pancreatitis Triglycerides do not require investigation or treatment unless they are higher than 500 mg/dL. (Treatment/investigation at higher than

2018 Kaiser Permanente Clinical Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>